GEN biotechnology最新文献

{"title":"Drug Pricing Versus Precision Medicine","authors":"Kevin Davies","doi":"10.1089/genbio.2023.29124.kda","DOIUrl":"https://doi.org/10.1089/genbio.2023.29124.kda","url":null,"abstract":"","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"129 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138988989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revelry and Reminiscence: 50 Years of Recombinant DNA at Cold Spring Harbor Laboratory","authors":"Fay Lin","doi":"10.1089/genbio.2023.29122.fli","DOIUrl":"https://doi.org/10.1089/genbio.2023.29122.fli","url":null,"abstract":"","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"65 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139013095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landmark CRISPR Approvals and the Rise of Epigenome Editing","authors":"G. Livshits","doi":"10.1089/genbio.2023.29123.gli","DOIUrl":"https://doi.org/10.1089/genbio.2023.29123.gli","url":null,"abstract":"","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"58 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138985998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sweet Dreams are Made of This: An Interview with Carolyn Bertozzi","authors":"Carolyn Bertozzi, Alex Philippidis, Kevin Davies","doi":"10.1089/genbio.2023.29119.cbe","DOIUrl":"https://doi.org/10.1089/genbio.2023.29119.cbe","url":null,"abstract":"","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"399 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI, Bias, and Discrimination","authors":"Hana El-Samad","doi":"10.1089/genbio.2023.29126.editorial","DOIUrl":"https://doi.org/10.1089/genbio.2023.29126.editorial","url":null,"abstract":"","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"437 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139018253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The RNA-Recognition Pathway: An Overlooked Transportation Mechanism for Extracellular and Therapeutic RNAs","authors":"Alice Ghidini, Aleksandra Singh","doi":"10.1089/genbio.2023.0049","DOIUrl":"https://doi.org/10.1089/genbio.2023.0049","url":null,"abstract":"","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"111 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139015491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Call for Special Issue Papers: Diversity, Equity, and Inclusion in Biotechnology","authors":"Brian Aguado, Karmella Haynes, Ana Maria Porras","doi":"10.1089/genbio.2023.29118.cfp","DOIUrl":"https://doi.org/10.1089/genbio.2023.29118.cfp","url":null,"abstract":"","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"32 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139262809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Mediated Computer-Aided Design of Viral Gene Therapies","authors":"Alireza Daneshvar, Stefan N. Lukianov","doi":"10.1089/genbio.2023.0014","DOIUrl":"https://doi.org/10.1089/genbio.2023.0014","url":null,"abstract":"Over 5% of newborns suffer from a genetic disease. These include single gene, polygenic, and chromosomal disorders. Many other noncongenital diseases with genetic components are activated by environmental triggers (autoimmune, cancer, and tissue injury). Sophisticated viral gene therapies could treat, and possibly cure, these diseases and significantly ease patient burden and improve quality of life. Current viral therapies are mostly limited to plasmid-based and adeno-associated virus variants with inefficient response rates and limited use, with some herpes, lenti, and retroviral modalities. Development is slow and expensive. Virtual prototyping of viral gene therapies through computational design, like in other engineering fields, may represent a useful process to accelerate and expand viral pipeline development by opening the human virome to therapeutic development and constructing specificity, potency, efficacy, and safety in silico. Contemporary computational tools (artificial intelligence, machine and deep learning, computer-aided design, high performance computing, cloud and edge computing, and physics-based modeling) now render this possibility feasible and, therefore, constitute powerful options for biopharma researchers to expand and accelerate precision medicine research and development for complex indications.","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"28 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136311682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the Spatial Proteome of Head and Neck Tumors: Key Immune Mediators and Metabolic Determinants in the Tumor Microenvironment","authors":"Niyati Jhaveri, Bassem Ben Cheikh, Nadezhda Nikulina, Ning Ma, Dmytro Klymyshyn, James DeRosa, Ritu Mihani, Aditya Pratapa, Yasmin Kassim, Sidharth Bommakanti, Olive Shang, Shannon Berry, Nicholas Ihley, Michael McLane, Yan He, Yi Zheng, James Monkman, Caroline Cooper, Ken O'Byrne, Bhaskar Anand, Michael Prater, Subham Basu, Brett G.M. Hughes, Arutha Kulasinghe, Oliver Braubach","doi":"10.1089/genbio.2023.0029","DOIUrl":"https://doi.org/10.1089/genbio.2023.0029","url":null,"abstract":"Head and neck squamous cell carcinomas (HNSCCs) are the seventh most common cancer and represent a global health burden. Immune checkpoint inhibitors (ICIs) have shown promise in treating recurrent/metastatic disease with durable benefit in ∼30% of patients. Current biomarkers for HNSCC are limited in their dynamic ability to capture tumor microenvironment (TME) features with an increasing need for deeper tissue characterization. Therefore, new biomarkers are needed to accurately stratify patients and predict responses to therapy. Here, we have optimized and applied an ultra-high plex, single-cell spatial protein analysis in HNSCC. Tissues were analyzed with a panel of 101 antibodies that targeted biomarkers related to tumor immune, metabolic and stress microenvironments. Our data uncovered a high degree of intra-tumoral heterogeneity intrinsic to HNSCC and provided unique insights into the biology of the disease. In particular, a cellular neighborhood analysis revealed the presence of six unique spatial neighborhoods enriched in functionally specialized immune subsets. In addition, functional phenotyping based on key metabolic and stress markers identified four distinct tumor regions with differential protein signatures. One region was marked by infiltration of CD8+ cytotoxic T cells and overexpression of BAK, a proapoptotic regulator, suggesting strong immune activation and stress. Another adjacent region within the same tumor had high expression of G6PD and MMP9, known drivers of tumor resistance and invasion, respectively. This dichotomy of immune activation-induced death and tumor progression in the same sample demonstrates the heterogenous niches and competing microenvironments that may underpin variable clinical responses. Our data integrate single-cell ultra-high plex spatial information with the functional state of the TME to provide insights into HNSCC biology and differential responses to ICI therapy. We believe that the approach outlined in this study will pave the way toward a new understanding of TME features associated with response and sensitivity to ICI therapies.","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135809421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Engineering CRISPR Cures: An Interview with Fyodor Urnov","authors":"Fyodor D. Urnov, Jonathan D. Grinstein","doi":"10.1089/genbio.2023.29113.fdu","DOIUrl":"https://doi.org/10.1089/genbio.2023.29113.fdu","url":null,"abstract":"GEN BiotechnologyVol. 2, No. 5 Asked & AnsweredFree AccessEngineering CRISPR Cures: An Interview with Fyodor UrnovFyodor D. Urnov and Jonathan D. GrinsteinFyodor D. Urnov*Address correspondence to: Fyodor D. Urnov, Director of the Center for Translational Genomics at the Innovative Genomics Institute. E-mail Address: [email protected]Director of the Center for Translational Genomics at the Innovative Genomics Institute.Search for more papers by this author and Jonathan D. GrinsteinSenior Editor, GEN Media Group.Search for more papers by this authorPublished Online:16 Oct 2023https://doi.org/10.1089/genbio.2023.29113.fduAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail Fyodor Urnov, Director of the Center for Translational Genomics at the Innovative Genomics Institute (IGI)Fyodor Urnov is a pioneer in the field of genome editing and one of the scientists most invested in expanding the availability and utility of CRISPR-based therapies to the broadest possible population. He envisions a world in which genome editing can treat the nearly 400 million people who are suffering from one of the 7000 diseases brought on by gene mutations.After his PhD in 1996 from Brown University, Urnov worked as a postdoctoral fellow in the laboratory of Alan Wolffe at the National Institutes of Health (NIH). In 2000, Urnov joined Wolffe in moving to Sangamo Therapeutics in California. During his 16 years at Sangamo, Urnov and his colleagues performed the first demonstration using zinc-finger nucleases to modify DNA in human cells in 2005, coining the term “genome editing” in the process.1After that, Urnov led collaborative teams that created large-scale genome editing applications in crop genetics, model animal reverse genetics, and human somatic cell genetics. While at Sangamo, Urnov also led a cross-functional team from basic discovery to the initial design of the first-in-human clinical trials for sickle cell disease and beta-thalassemia, which are being conducted in collaboration with UCSF Benioff Children's Hospital and UCLA Broad Stem Cell Research Center.In 2019, Urnov became the Director of the Center for Translational Genomics at the Innovative Genomics Institute (IGI), working alongside Nobel laureate Jennifer Doudna, and a Professor in the Departments of Genetics, Genomics, and Development at the University of California, Berkeley. At the IGI, Urnov works in collaborative teams to develop first-in-human applications of experimental CRISPR-based therapeutics for sickle cell disease (with Mark Walters, UCSF), genetic disorders of the immune system (with Alexander Marson, UCSF/IGI), radiation injury (with Jonathan Weissman, MIT/Whitehead Institute), cystic fibrosis (with Ross Wilson, IGI), and neurological disorders (with Weill Neurohub and Roche/Genentech).In this exclusive interview, GEN Biotechnology talks to Urnov about his career in ","PeriodicalId":73134,"journal":{"name":"GEN biotechnology","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135810519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}